PACIRA BIOSCIENCES, INC. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Settlements
PACIRA BIOSCIENCES, INC. (PCRX) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Settlements of $13.60 million for the 12-month period ending 2025-12-31, per its 10-Q filed 2026-08-04.
Financial Statements › Notes › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation › Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases, (Sales), Issuances, (Settlements)
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements · last filed 2026-08-04
- PACIRA BIOSCIENCES, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, settlements for the quarter ending 2025-12-31 was -$38.00K.
- PACIRA BIOSCIENCES, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, settlements for the quarter ending 2025-09-30 was $0.00.
- PACIRA BIOSCIENCES, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, settlements for the quarter ending 2025-06-30 was $0.00.
- PACIRA BIOSCIENCES, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, settlements for the quarter ending 2025-03-31 was $13.64M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Settlements 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Settlements 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Settlements 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Settlements 12 month |
|---|---|---|---|---|
| 2025-12-31 | -$38.00K derived: 10-Q 12 month − 10-Q 9 month · filed 2026-08-04 | -$38.00K derived: sum of 2 quarters · filed 2026-08-04 | -$38.00K derived: sum of 3 quarters · filed 2026-08-04 | $13.60M 10-Q · filed 2026-08-04 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $0.00 derived: sum of 2 quarters · filed 2025-11-06 | $13.64M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $13.64M 10-Q · filed 2025-08-05 | ||
| 2025-03-31 | $13.64M 10-Q · filed 2025-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |